{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:44:34Z","timestamp":1790765074098,"version":"4.1.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001870","name":"Fundacja na rzecz Nauki Polskiej","doi-asserted-by":"publisher","award":["TEAM\/2017-4\/32"],"award-info":[{"award-number":["TEAM\/2017-4\/32"]}],"id":[{"id":"10.13039\/501100001870","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Wroclaw University of Science and Technology for support for the Department of Organic and Medicinal Chemistry","award":["Statute Funds 82013902"],"award-info":[{"award-number":["Statute Funds 82013902"]}]},{"name":"Medical Research Agency in Poland","award":["2020\/ABM\/SARS\/1"],"award-info":[{"award-number":["2020\/ABM\/SARS\/1"]}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR200030"],"award-info":[{"award-number":["RR200030"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH","award":["NIH R01 GM115568"],"award-info":[{"award-number":["NIH R01 GM115568"]}]},{"name":"ERDF\/ESF project ChemBioDrug","award":["CZ.02.1.01\/0.0\/0.0\/16_019\/0000729"],"award-info":[{"award-number":["CZ.02.1.01\/0.0\/0.0\/16_019\/0000729"]}]},{"DOI":"10.13039\/501100010099","name":"\u00dastav organick\u00e9 chemie a biochemie Akademie v\u011bd \u010cesk\u00e9 republiky","doi-asserted-by":"publisher","award":["RVO 61388963"],"award-info":[{"award-number":["RVO 61388963"]}],"id":[{"id":"10.13039\/501100010099","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SCORE project of the European Union","award":["101003627"],"award-info":[{"award-number":["101003627"]}]},{"DOI":"10.13039\/100009139","name":"German Center for Infection Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Government of Schleswig-Holstein through its Structure and Excellence Fund"},{"name":"Possehl Foundation"},{"name":"National Science Centre in Poland","award":["2020\/01\/0\/ST4\/00124"],"award-info":[{"award-number":["2020\/01\/0\/ST4\/00124"]}]},{"name":"National Science Centre in Poland","award":["2020\/01\/0\/NZ1\/00063"],"award-info":[{"award-number":["2020\/01\/0\/NZ1\/00063"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Proteases encoded by SARS-CoV-2 constitute a promising target for new therapies against COVID-19. SARS-CoV-2 main protease (M\n                    <jats:sup>pro<\/jats:sup>\n                    , 3CL\n                    <jats:sup>pro<\/jats:sup>\n                    ) and papain-like protease (PL\n                    <jats:sup>pro<\/jats:sup>\n                    ) are responsible for viral polyprotein cleavage\u2014a process crucial for viral survival and replication. Recently it was shown that 2-phenylbenzisoselenazol-3(2\n                    <jats:italic>H<\/jats:italic>\n                    )-one (ebselen), an organoselenium anti-inflammatory small-molecule drug, is a potent, covalent inhibitor of both the proteases and its potency was evaluated in enzymatic and antiviral assays. In this study, we screened a collection of 34 ebselen and ebselen diselenide derivatives for SARS-CoV-2 PL\n                    <jats:sup>pro<\/jats:sup>\n                    and M\n                    <jats:sup>pro<\/jats:sup>\n                    inhibitors. Our studies revealed that ebselen derivatives are potent inhibitors of both the proteases. We identified three PL\n                    <jats:sup>pro<\/jats:sup>\n                    and four M\n                    <jats:sup>pro<\/jats:sup>\n                    inhibitors superior to ebselen. Independently, ebselen was shown to inhibit the N7-methyltransferase activity of SARS-CoV-2 nsp14 protein involved in viral RNA cap modification. Hence, selected compounds were also evaluated as nsp14 inhibitors. In the second part of our work, we employed 11 ebselen analogues\u2014bis(2-carbamoylaryl)phenyl diselenides\u2014in biological assays to evaluate their anti-SARS-CoV-2 activity in Vero E6 cells. We present their antiviral and cytoprotective activity and also low cytotoxicity. Our work shows that ebselen, its derivatives, and diselenide analogues constitute a promising platform for development of new antivirals targeting the SARS-CoV-2 virus.\n                  <\/jats:p>","DOI":"10.1038\/s41598-023-35907-w","type":"journal-article","created":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T13:04:18Z","timestamp":1686056658000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Ebselen derivatives inhibit SARS-CoV-2 replication by inhibition of its essential proteins: PLpro and Mpro proteases, and nsp14 guanine N7-methyltransferase"],"prefix":"10.1038","volume":"13","author":[{"given":"Mikolaj","family":"Zmudzinski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wioletta","family":"Rut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamila","family":"Olech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaros\u0142aw","family":"Granda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miros\u0142aw","family":"Giurg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Burda-Grabowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafa\u0142","family":"Kaleta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michala","family":"Zgarbova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Kasprzyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyuanyuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongyang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Digant","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Kesik-Brodacka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun K.","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Hilgenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Jemielity","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Drag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,6]]},"reference":[{"issue":"10223","key":"35907_CR1","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/S0140-6736(20)30185-9","volume":"395","author":"C Wang","year":"2020","unstructured":"Wang, C. et al. A novel coronavirus outbreak of global health concern. Lancet 395(10223), 470\u2013473 (2020).","journal-title":"Lancet"},{"issue":"7798","key":"35907_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"F Wu","year":"2020","unstructured":"Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature 579(7798), 265\u2013269 (2020).","journal-title":"Nature"},{"issue":"4","key":"35907_CR3","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41591-020-0820-9","volume":"26","author":"KG Andersen","year":"2020","unstructured":"Andersen, K. G. et al. The proximal origin of SARS-CoV-2. Nat. Med. 26(4), 450\u2013452 (2020).","journal-title":"Nat. Med."},{"issue":"5","key":"35907_CR4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","volume":"20","author":"E Dong","year":"2020","unstructured":"Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. 20(5), 533\u2013534 (2020).","journal-title":"Lancet Infect. Dis."},{"issue":"7","key":"35907_CR5","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","volume":"19","author":"WT Harvey","year":"2021","unstructured":"Harvey, W. T. et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 19(7), 409\u2013424 (2021).","journal-title":"Nat. Rev. Microbiol."},{"issue":"1","key":"35907_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41541-021-00369-6","volume":"6","author":"FX Heinz","year":"2021","unstructured":"Heinz, F. X. & Stiasny, K. Distinguishing features of current COVID-19 vaccines: Knowns and unknowns of antigen presentation and modes of action. NPJ Vaccines 6(1), 104 (2021).","journal-title":"NPJ Vaccines"},{"issue":"5","key":"35907_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nrd.2015.37","volume":"15","author":"A Zumla","year":"2016","unstructured":"Zumla, A. et al. Coronaviruses\u2014Drug discovery and therapeutic options. Nat. Rev. Drug Discov. 15(5), 327\u2013347 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"35907_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117592","volume":"253","author":"AA Elfiky","year":"2020","unstructured":"Elfiky, A. A. Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci. 253, 117592 (2020).","journal-title":"Life Sci."},{"issue":"7811","key":"35907_CR9","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","volume":"582","author":"Z Jin","year":"2020","unstructured":"Jin, Z. et al. Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature 582(7811), 289\u2013293 (2020).","journal-title":"Nature"},{"key":"35907_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117627","volume":"251","author":"M Kandeel","year":"2020","unstructured":"Kandeel, M. & Al-Nazawi, M. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease. Life Sci. 251, 117627 (2020).","journal-title":"Life Sci."},{"key":"35907_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2020.104241","volume":"146","author":"E Khodadadi","year":"2020","unstructured":"Khodadadi, E. et al. Study of combining virtual screening and antiviral treatments of the Sars-CoV-2 (Covid-19). Microb. Pathog. 146, 104241 (2020).","journal-title":"Microb. Pathog."},{"issue":"7","key":"35907_CR12","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00210-020-01901-6","volume":"393","author":"M Rameshrad","year":"2020","unstructured":"Rameshrad, M. et al. A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19). Naunyn Schmiedebergs Arch. Pharmacol. 393(7), 1137\u20131152 (2020).","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"issue":"17","key":"35907_CR13","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.4155\/fmc-2020-0147","volume":"12","author":"S Joshi","year":"2020","unstructured":"Joshi, S., Joshi, M. & Degani, M. S. Tackling SARS-CoV-2: Proposed targets and repurposed drugs. Future Med. Chem. 12(17), 1579\u20131601 (2020).","journal-title":"Future Med. Chem."},{"issue":"19","key":"35907_CR14","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel, J. H. et al. Remdesivir for the treatment of Covid-19\u2014Final report. N. Engl. J. Med. 383(19), 1813\u20131826 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"35907_CR15","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2023184","volume":"384","author":"WHOST Consortium","year":"2021","unstructured":"WHOST Consortium. Repurposed antiviral drugs for Covid-19\u2014Interim WHO solidarity trial results. N. Engl. J. Med. 384(6), 497\u2013511 (2021).","journal-title":"N. Engl. J. Med."},{"key":"35907_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","volume":"1282","author":"AR Fehr","year":"2015","unstructured":"Fehr, A. R. & Perlman, S. Coronaviruses: An overview of their replication and pathogenesis. Methods Mol. Biol. 1282, 1\u201323 (2015).","journal-title":"Methods Mol. Biol."},{"issue":"18","key":"35907_CR17","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1111\/febs.12936","volume":"281","author":"R Hilgenfeld","year":"2014","unstructured":"Hilgenfeld, R. From SARS to MERS: Crystallographic studies on coronaviral proteases enable antiviral drug design. FEBS J. 281(18), 4085\u20134096 (2014).","journal-title":"FEBS J."},{"issue":"6489","key":"35907_CR18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.abb3405","volume":"368","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors. Science 368(6489), 409\u2013412 (2020).","journal-title":"Science"},{"issue":"5626","key":"35907_CR19","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1126\/science.1085658","volume":"300","author":"K Anand","year":"2003","unstructured":"Anand, K. et al. Coronavirus main proteinase (3CLpro) structure: Basis for design of anti-SARS drugs. Science 300(5626), 1763\u20131767 (2003).","journal-title":"Science"},{"issue":"3","key":"35907_CR20","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1074\/jbc.M310875200","volume":"279","author":"K Fan","year":"2004","unstructured":"Fan, K. et al. Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase. J. Biol. Chem. 279(3), 1637\u20131642 (2004).","journal-title":"J. Biol. Chem."},{"issue":"6","key":"35907_CR21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1021\/acscombsci.0c00058","volume":"22","author":"B Goyal","year":"2020","unstructured":"Goyal, B. & Goyal, D. Targeting the dimerization of the main protease of coronaviruses: A potential broad-spectrum therapeutic strategy. ACS Combin. Sci. 22(6), 297\u2013305 (2020).","journal-title":"ACS Combin. Sci."},{"issue":"2","key":"35907_CR22","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41589-020-00689-z","volume":"17","author":"W Rut","year":"2021","unstructured":"Rut, W. et al. SARS-CoV-2 M(pro) inhibitors and activity-based probes for patient-sample imaging. Nat. Chem. Biol. 17(2), 222\u2013228 (2021).","journal-title":"Nat. Chem. Biol."},{"issue":"10","key":"35907_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0030324","volume":"3","author":"H Yang","year":"2005","unstructured":"Yang, H. et al. Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol. 3(10), e324 (2005).","journal-title":"PLoS Biol."},{"issue":"8","key":"35907_CR24","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1021\/acsinfecdis.0c00168","volume":"6","author":"BT Freitas","year":"2020","unstructured":"Freitas, B. T. et al. Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-CoV-2 papain-like protease. ACS Infect. Dis. 6(8), 2099\u20132109 (2020).","journal-title":"ACS Infect. Dis."},{"issue":"18","key":"35907_CR25","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020106275","volume":"39","author":"T Klemm","year":"2020","unstructured":"Klemm, T. et al. Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2. EMBO J. 39(18), e106275 (2020).","journal-title":"EMBO J."},{"issue":"42","key":"35907_CR26","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd4596","volume":"6","author":"W Rut","year":"2020","unstructured":"Rut, W. et al. Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti-COVID-19 drug design. Sci. Adv. 6(42), eabd4596 (2020).","journal-title":"Sci. Adv."},{"issue":"7835","key":"35907_CR27","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","volume":"587","author":"D Shin","year":"2020","unstructured":"Shin, D. et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature 587(7835), 657\u2013662 (2020).","journal-title":"Nature"},{"key":"35907_CR28","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/cber.19240570703","volume":"57","author":"R Lesser","year":"1924","unstructured":"Lesser, R. & Wei\u00df, R. \u00dcber selenhaltige aromatische Verbindungen (VI). Ber. dtsch. Chem. Ges. A\/B 57, 1077\u20131082 (1924).","journal-title":"Ber. dtsch. Chem. Ges. A\/B"},{"issue":"7","key":"35907_CR29","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1021\/cr000426w","volume":"101","author":"G Mugesh","year":"2001","unstructured":"Mugesh, G., du Mont, W. W. & Sies, H. Chemistry of biologically important synthetic organoselenium compounds. Chem. Rev. 101(7), 2125\u20132179 (2001).","journal-title":"Chem. Rev."},{"issue":"23","key":"35907_CR30","doi-asserted-by":"publisher","first-page":"12075","DOI":"10.1021\/ic201603v","volume":"50","author":"S Antony","year":"2011","unstructured":"Antony, S. & Bayse, C. A. Modeling the mechanism of the glutathione peroxidase mimic ebselen. Inorg. Chem. 50(23), 12075\u201312084 (2011).","journal-title":"Inorg. Chem."},{"issue":"8","key":"35907_CR31","doi-asserted-by":"publisher","first-page":"4865","DOI":"10.1007\/s11033-014-3417-x","volume":"41","author":"GK Azad","year":"2014","unstructured":"Azad, G. K. & Tomar, R. S. Ebselen, a promising antioxidant drug: Mechanisms of action and targets of biological pathways. Mol. Biol. Rep. 41(8), 4865\u20134879 (2014).","journal-title":"Mol. Biol. Rep."},{"issue":"34","key":"35907_CR32","doi-asserted-by":"publisher","first-page":"10603","DOI":"10.1002\/chem.200801258","volume":"14","author":"BK Sarma","year":"2008","unstructured":"Sarma, B. K. & Mugesh, G. Antioxidant activity of the anti-inflammatory compound ebselen: A reversible cyclization pathway via selenenic and seleninic acid intermediates. Chemistry 14(34), 10603\u201310614 (2008).","journal-title":"Chemistry"},{"issue":"11","key":"35907_CR33","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1021\/ar100059g","volume":"43","author":"KP Bhabak","year":"2010","unstructured":"Bhabak, K. P. & Mugesh, G. Functional mimics of glutathione peroxidase: Bioinspired synthetic antioxidants. Acc. Chem. Res. 43(11), 1408\u20131419 (2010).","journal-title":"Acc. Chem. Res."},{"issue":"1","key":"35907_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0009-2797(92)90122-2","volume":"84","author":"R Morgenstern","year":"1992","unstructured":"Morgenstern, R., Cotgreave, I. A. & Engman, L. Determination of the relative contributions of the diselenide and selenol forms of ebselen in the mechanism of its glutathione peroxidase-like activity. Chem. Biol. Interact. 84(1), 77\u201384 (1992).","journal-title":"Chem. Biol. Interact."},{"issue":"38","key":"35907_CR35","doi-asserted-by":"publisher","first-page":"4959","DOI":"10.1016\/j.tet.2018.05.027","volume":"74","author":"KN Sands","year":"2018","unstructured":"Sands, K. N. & Back, T. G. Key steps and intermediates in the catalytic mechanism for the reduction of peroxides by the antioxidant ebselen. Tetrahedron 74(38), 4959\u20134967 (2018).","journal-title":"Tetrahedron"},{"issue":"3","key":"35907_CR36","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/0891-5849(93)90028-S","volume":"14","author":"H Sies","year":"1993","unstructured":"Sies, H. Ebselen, a selenoorganic compound as glutathione peroxidase mimic. Free Radic. Biol. Med. 14(3), 313\u2013323 (1993).","journal-title":"Free Radic. Biol. Med."},{"issue":"11","key":"35907_CR37","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1016\/j.bbagen.2018.03.031","volume":"1862","author":"JL Wedding","year":"2018","unstructured":"Wedding, J. L. et al. Investigation into the intracellular fates, speciation and mode of action of selenium-containing neuroprotective agents using XAS and XFM. Biochim. Biophys. Acta Gen. Subj. 1862(11), 2393\u20132404 (2018).","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"issue":"1","key":"35907_CR38","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1038\/s41598-021-83229-6","volume":"11","author":"E Weglarz-Tomczak","year":"2021","unstructured":"Weglarz-Tomczak, E. et al. Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2. Sci. Rep. 11(1), 3640 (2021).","journal-title":"Sci. Rep."},{"issue":"1","key":"35907_CR39","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1038\/s41467-021-23313-7","volume":"12","author":"K Amporndanai","year":"2021","unstructured":"Amporndanai, K. et al. Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives. Nat. Commun. 12(1), 3061 (2021).","journal-title":"Nat. Commun."},{"key":"35907_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2014.11.010","volume":"114","author":"J Cao","year":"2015","unstructured":"Cao, J., Forrest, J. C. & Zhang, X. A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs. Antivir. Res. 114, 1\u201310 (2015).","journal-title":"Antivir. Res."},{"issue":"13","key":"35907_CR41","doi-asserted-by":"publisher","first-page":"7048","DOI":"10.3390\/ijms22137048","volume":"22","author":"F Mangiavacchi","year":"2021","unstructured":"Mangiavacchi, F. et al. Seleno-functionalization of quercetin improves the non-covalent inhibition of M(pro) and its antiviral activity in cells against SARS-CoV-2. Int. J. Mol. Sci. 22(13), 7048 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"35907_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2021.105142","volume":"193","author":"R Kasprzyk","year":"2021","unstructured":"Kasprzyk, R. et al. Identification and evaluation of potential SARS-CoV-2 antiviral agents targeting mRNA cap guanine N7-Methyltransferase. Antivir. Res. 193, 105142 (2021).","journal-title":"Antivir. Res."},{"issue":"9","key":"35907_CR43","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1073\/pnas.0808790106","volume":"106","author":"Y Chen","year":"2009","unstructured":"Chen, Y. et al. Functional screen reveals SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase. Proc. Natl. Acad. Sci. U.S.A. 106(9), 3484\u20133489 (2009).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"4","key":"35907_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000863","volume":"6","author":"M Bouvet","year":"2010","unstructured":"Bouvet, M. et al. In vitro reconstitution of SARS-coronavirus mRNA cap methylation. PLoS Pathog. 6(4), e1000863 (2010).","journal-title":"PLoS Pathog."},{"issue":"1","key":"35907_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2008.05.003","volume":"80","author":"H Dong","year":"2008","unstructured":"Dong, H., Zhang, B. & Shi, P. Y. Flavivirus methyltransferase: A novel antiviral target. Antivir. Res. 80(1), 1\u201310 (2008).","journal-title":"Antivir. Res."},{"issue":"2","key":"35907_CR46","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2174\/187152609787847659","volume":"9","author":"TR Tong","year":"2009","unstructured":"Tong, T. R. Drug targets in severe acute respiratory syndrome (SARS) virus and other coronavirus infections. Infect. Disord. Drug Targets 9(2), 223\u2013245 (2009).","journal-title":"Infect. Disord. Drug Targets"},{"issue":"37","key":"35907_CR47","doi-asserted-by":"publisher","first-page":"12910","DOI":"10.1074\/jbc.REV120.013930","volume":"295","author":"E Hartenian","year":"2020","unstructured":"Hartenian, E. et al. The molecular virology of coronaviruses. J. Biol. Chem. 295(37), 12910\u201312934 (2020).","journal-title":"J. Biol. Chem."},{"issue":"1","key":"35907_CR48","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41580-021-00432-z","volume":"23","author":"B Malone","year":"2022","unstructured":"Malone, B. et al. Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design. Nat. Rev. Mol. Cell Biol. 23(1), 21\u201339 (2022).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"24","key":"35907_CR49","doi-asserted-by":"publisher","first-page":"9601","DOI":"10.1021\/acs.jmedchem.5b01183","volume":"58","author":"L Sancineto","year":"2015","unstructured":"Sancineto, L. et al. Design and synthesis of DiselenoBisBenzamides (DISeBAs) as nucleocapsid protein 7 (NCp7) inhibitors with anti-HIV activity. J. Med. Chem. 58(24), 9601\u20139614 (2015).","journal-title":"J. Med. Chem."},{"issue":"4","key":"35907_CR50","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1128\/AAC.02574-15","volume":"60","author":"S Thenin-Houssier","year":"2016","unstructured":"Thenin-Houssier, S. et al. Ebselen, a small-molecule capsid inhibitor of HIV-1 replication. Antimicrob. Agents Chemother. 60(4), 2195\u20132208 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"35907_CR51","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1002\/jcb.25457","volume":"117","author":"G Sartori","year":"2016","unstructured":"Sartori, G. et al. Antiviral action of diphenyl diselenide on herpes simplex virus 2 infection in female BALB\/c mice. J. Cell. Biochem. 117(7), 1638\u20131648 (2016).","journal-title":"J. Cell. Biochem."},{"issue":"10","key":"35907_CR52","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1021\/cb500512z","volume":"9","author":"S Mukherjee","year":"2014","unstructured":"Mukherjee, S. et al. Ebselen inhibits hepatitis C virus NS3 helicase binding to nucleic acid and prevents viral replication. ACS Chem. Biol. 9(10), 2393\u20132403 (2014).","journal-title":"ACS Chem. Biol."},{"issue":"2","key":"35907_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006854","volume":"14","author":"Y Simanjuntak","year":"2018","unstructured":"Simanjuntak, Y. et al. Ebselen alleviates testicular pathology in mice with Zika virus infection and prevents its sexual transmission. PLoS Pathog. 14(2), e1006854 (2018).","journal-title":"PLoS Pathog."},{"issue":"42","key":"35907_CR54","doi-asserted-by":"publisher","first-page":"39456","DOI":"10.1074\/jbc.M206452200","volume":"277","author":"R Zhao","year":"2002","unstructured":"Zhao, R. & Holmgren, A. A novel antioxidant mechanism of ebselen involving ebselen diselenide, a substrate of mammalian thioredoxin and thioredoxin reductase. J. Biol. Chem. 277(42), 39456\u201339462 (2002).","journal-title":"J. Biol. Chem."},{"issue":"1","key":"35907_CR55","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2174\/2213346103666160127003506","volume":"3","author":"JB Azeredo","year":"2016","unstructured":"Azeredo, J. B., Schwab, R. S. & Braga, A. L. Synthesis of biologically active selenium-containing molecules from greener perspectives. Curr. Green Chem. 3(1), 51\u201367 (2016).","journal-title":"Curr. Green Chem."},{"issue":"8","key":"35907_CR56","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1039\/C4OB00027G","volume":"12","author":"SJ Balkrishna","year":"2014","unstructured":"Balkrishna, S. J. et al. An ebselen like catalyst with enhanced GPx activity via a selenol intermediate. Org. Biomol. Chem. 12(8), 1215\u20131219 (2014).","journal-title":"Org. Biomol. Chem."},{"issue":"23","key":"35907_CR57","doi-asserted-by":"publisher","first-page":"5394","DOI":"10.1021\/ol102027j","volume":"12","author":"SJ Balkrishna","year":"2010","unstructured":"Balkrishna, S. J. et al. Cu-catalyzed efficient synthetic methodology for ebselen and related Se-N heterocycles. Org. Lett. 12(23), 5394\u20135397 (2010).","journal-title":"Org. Lett."},{"issue":"49","key":"35907_CR58","doi-asserted-by":"publisher","first-page":"9565","DOI":"10.1016\/j.tet.2011.09.141","volume":"67","author":"SJ Balkrishna","year":"2011","unstructured":"Balkrishna, S. J., Bhakuni, B. S. & Kumar, S. Copper catalyzed\/mediated synthetic methodology for ebselen and related isoselenazolones. Tetrahedron 67(49), 9565\u20139575 (2011).","journal-title":"Tetrahedron"},{"issue":"37","key":"35907_CR59","doi-asserted-by":"publisher","first-page":"7531","DOI":"10.1016\/S0040-4020(02)00789-5","volume":"58","author":"M Osajda","year":"2002","unstructured":"Osajda, M. & M\u0142ochowski, J. The reactions of 2-(chloroseleno)benzoyl chloride with nucleophiles. Tetrahedron 58(37), 7531\u20137537 (2002).","journal-title":"Tetrahedron"},{"issue":"6","key":"35907_CR60","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3390\/molecules22060974","volume":"22","author":"M Giurg","year":"2017","unstructured":"Giurg, M. et al. Reaction of bis[(2-chlorocarbonyl)phenyl] diselenide with phenols, aminophenols, and other amines towards diphenyl diselenides with antimicrobial and antiviral properties. Molecules 22(6), 974 (2017).","journal-title":"Molecules"},{"issue":"11","key":"35907_CR61","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/jlac.199619961108","volume":"1996","author":"J Mlochowski","year":"1996","unstructured":"Mlochowski, J. et al. Synthesis and properties of 2-carboxyalkyl-1,2-benzisoselenazol-3(2H)-ones and related organoselenium compounds as nitric oxide synthase inhibitors and cytokine inducers. Liebigs Ann. 1996(11), 1751\u20131755 (1996).","journal-title":"Liebigs Ann."},{"issue":"4","key":"35907_CR62","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1080\/10426500801900956","volume":"183","author":"M Giurg","year":"2008","unstructured":"Giurg, M. & Syper, L. Diaryl diselenides and related compounds as oxygen-transfer agents. Phosphorus Sulfur Silicon Relat. Elem. 183(4), 970\u2013985 (2008).","journal-title":"Phosphorus Sulfur Silicon Relat. Elem."},{"issue":"2","key":"35907_CR63","doi-asserted-by":"publisher","first-page":"546","DOI":"10.24820\/ark.5550190.p009.797","volume":"2017","author":"M Pi\u0119tka-Ottlik","year":"2017","unstructured":"Pi\u0119tka-Ottlik, M. et al. Synthesis of new alkylated and methoxylated analogues of ebselen with antiviral and antimicrobial properties. ARKIVOC 2017(2), 546\u2013556 (2017).","journal-title":"ARKIVOC"},{"issue":"21","key":"35907_CR64","doi-asserted-by":"publisher","first-page":"5254","DOI":"10.1016\/j.bmcl.2016.09.050","volume":"26","author":"E Weglarz-Tomczak","year":"2016","unstructured":"Weglarz-Tomczak, E. et al. Identification of methionine aminopeptidase 2 as a molecular target of the organoselenium drug ebselen and its derivatives\/analogues: Synthesis, inhibitory activity and molecular modeling study. Bioorg. Med. Chem. Lett. 26(21), 5254\u20135259 (2016).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"35907_CR65","first-page":"441","volume":"71","author":"P Bernatowicz","year":"1997","unstructured":"Bernatowicz, P. et al. A 13C, 15N and 77Se NMR study of some seleno and diseleno azines and related compounds. Pol. J. Chem. 71, 441\u2013445 (1997).","journal-title":"Pol. J. Chem."},{"issue":"90","key":"35907_CR66","doi-asserted-by":"publisher","first-page":"48959","DOI":"10.1039\/C4RA08631G","volume":"4","author":"AJ Pacu\u0142a","year":"2014","unstructured":"Pacu\u0142a, A. J., \u015acianowski, J. & Aleksandrzak, K. B. Highly efficient synthesis and antioxidant capacity of N-substituted benzisoselenazol-3(2H)-ones. RSC Adv. 4(90), 48959\u201348962 (2014).","journal-title":"RSC Adv."},{"issue":"49","key":"35907_CR67","doi-asserted-by":"publisher","first-page":"11266","DOI":"10.1002\/chem.202001036","volume":"26","author":"R Kasprzyk","year":"2020","unstructured":"Kasprzyk, R. et al. Direct high-throughput screening assay for mRNA cap guanine-N7 methyltransferase activity. Chemistry 26(49), 11266\u201311275 (2020).","journal-title":"Chemistry"},{"issue":"5","key":"35907_CR68","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.arcmed.2020.04.019","volume":"51","author":"L Delgado-Roche","year":"2020","unstructured":"Delgado-Roche, L. & Mesta, F. Oxidative stress as key player in severe acute respiratory syndrome coronavirus (SARS-CoV) infection. Arch. Med. Res. 51(5), 384\u2013387 (2020).","journal-title":"Arch. Med. Res."},{"issue":"8","key":"35907_CR69","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.tips.2020.05.005","volume":"41","author":"K Takayama","year":"2020","unstructured":"Takayama, K. In vitro and animal models for SARS-CoV-2 research. Trends Pharmacol. Sci. 41(8), 513\u2013517 (2020).","journal-title":"Trends Pharmacol. Sci."},{"issue":"37","key":"35907_CR70","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd0345","volume":"6","author":"CA Menendez","year":"2020","unstructured":"Menendez, C. A. et al. Molecular characterization of ebselen binding activity to SARS-CoV-2 main protease. Sci. Adv. 6(37), eabd0345 (2020).","journal-title":"Sci. Adv."},{"key":"35907_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2021.105455","volume":"117","author":"Z Qiao","year":"2021","unstructured":"Qiao, Z. et al. The Mpro structure-based modifications of ebselen derivatives for improved antiviral activity against SARS-CoV-2 virus. Bioorg. Chem. 117, 105455 (2021).","journal-title":"Bioorg. Chem."},{"issue":"6","key":"35907_CR72","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1021\/acsptsci.0c00130","volume":"3","author":"C Ma","year":"2020","unstructured":"Ma, C. et al. Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are nonspecific promiscuous SARS-CoV-2 main protease inhibitors. ACS Pharmacol. Transl. Sci. 3(6), 1265\u20131277 (2020).","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"4","key":"35907_CR73","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/j.apsb.2021.10.026","volume":"12","author":"C Ma","year":"2022","unstructured":"Ma, C. et al. Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays. Acta Pharm. Sin. B 12(4), 1636\u20131651 (2022).","journal-title":"Acta Pharm. Sin. B"},{"issue":"7","key":"35907_CR74","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00044-022-02903-0","volume":"31","author":"H Tan","year":"2022","unstructured":"Tan, H., Ma, C. & Wang, J. Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor. Med. Chem. Res. 31(7), 1147\u20131153 (2022).","journal-title":"Med. Chem. Res."},{"issue":"1","key":"35907_CR75","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s42003-022-03277-0","volume":"5","author":"E Heilmann","year":"2022","unstructured":"Heilmann, E. et al. A VSV-based assay quantifies coronavirus Mpro\/3CLpro\/Nsp5 main protease activity and chemical inhibition. Commun. Biol. 5(1), 391 (2022).","journal-title":"Commun. Biol."},{"issue":"4","key":"35907_CR76","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s00204-021-03003-5","volume":"95","author":"CW Nogueira","year":"2021","unstructured":"Nogueira, C. W., Barbosa, N. V. & Rocha, J. B. T. Toxicology and pharmacology of synthetic organoselenium compounds: An update. Arch. Toxicol. 95(4), 1179\u20131226 (2021).","journal-title":"Arch. Toxicol."},{"issue":"6","key":"35907_CR77","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1007\/s10930-020-09935-8","volume":"39","author":"S Suhail","year":"2020","unstructured":"Suhail, S. et al. Role of oxidative stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) infection: A review. Protein J. 39(6), 644\u2013656 (2020).","journal-title":"Protein J."},{"key":"35907_CR78","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3389\/fnut.2020.00143","volume":"7","author":"EW Taylor","year":"2020","unstructured":"Taylor, E. W. & Radding, W. Understanding selenium and glutathione as antiviral factors in COVID-19: Does the viral M(pro) protease target host selenoproteins and glutathione synthesis?. Front. Nutr. 7, 143 (2020).","journal-title":"Front. Nutr."},{"key":"35907_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.102199","volume":"48","author":"L Du","year":"2021","unstructured":"Du, L. et al. Oxidative stress transforms 3CLpro into an insoluble and more active form to promote SARS-CoV-2 replication. Redox. Biol. 48, 102199 (2021).","journal-title":"Redox. Biol."},{"issue":"01","key":"35907_CR80","doi-asserted-by":"publisher","first-page":"047","DOI":"10.1055\/s-0028-1111106","volume":"30","author":"E Lynch","year":"2009","unstructured":"Lynch, E. & Kil, J. Development of ebselen, a glutathione peroxidase mimic, for the prevention and treatment of noise-induced hearing loss. Semin. Hear. 30(01), 047\u2013055 (2009).","journal-title":"Semin. Hear."},{"issue":"12","key":"35907_CR81","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1007\/s00213-020-05654-1","volume":"237","author":"AL Sharpley","year":"2020","unstructured":"Sharpley, A. L. et al. A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania. Psychopharmacology 237(12), 3773\u20133782 (2020).","journal-title":"Psychopharmacology"},{"issue":"1","key":"35907_CR82","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1161\/01.STR.29.1.12","volume":"29","author":"T Yamaguchi","year":"1998","unstructured":"Yamaguchi, T. et al. Ebselen in acute ischemic stroke: A placebo-controlled, double-blind clinical trial. Ebselen Study Group. Stroke 29(1), 12\u201317 (1998).","journal-title":"Stroke"},{"key":"35907_CR83","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/ncomms2320","volume":"4","author":"N Singh","year":"2013","unstructured":"Singh, N. et al. A safe lithium mimetic for bipolar disorder. Nat. Commun. 4, 1332 (2013).","journal-title":"Nat. Commun."},{"issue":"21","key":"35907_CR84","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1055\/s-0034-1381011","volume":"47","author":"J Granda","year":"2015","unstructured":"Granda, J. et al. Synthesis of 7- and 8-functionalized 2-aminophenoxazinones via cyclocondensation of 2-aminophenols. Synthesis 47(21), 3321\u20133332 (2015).","journal-title":"Synthesis"},{"key":"35907_CR85","unstructured":"Welter, A., Christiaens, L. & Wirtz-Peitz, F. Benzisoselenazolones and processes for the treatment of rheumatic and arthritic diseases using them (1983)."},{"issue":"12","key":"35907_CR86","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/jlac.1993199301201","volume":"1993","author":"J M\u0142ochowski","year":"1993","unstructured":"M\u0142ochowski, J. et al. Aromatic and azaaromatic diselenides, benzisoselenazolones and related compounds as immunomodulators active in humans: Synthesis and properties. Liebigs Ann. Chem. 1993(12), 1239\u20131244 (1993).","journal-title":"Liebigs Ann. Chem."},{"key":"35907_CR87","unstructured":"Welter, A. et al. Diselenobis-benzoic acid amides of primary and secondary amines and processes for the treatment of diseases in humans caused by a cell injury (1989)."},{"issue":"3","key":"35907_CR88","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/ph9030043","volume":"9","author":"J Kuppers","year":"2016","unstructured":"Kuppers, J. et al. Convergent synthesis of two fluorescent ebselen-coumarin heterodimers. Pharmaceuticals (Basel) 9(3), 43 (2016).","journal-title":"Pharmaceuticals (Basel)"},{"issue":"12","key":"35907_CR89","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1248\/cpb.51.1413","volume":"51","author":"TC Chang","year":"2003","unstructured":"Chang, T. C. et al. Synthesis and biological evaluation of ebselen and its acyclic derivatives. Chem. Pharm. Bull. (Tokyo) 51(12), 1413\u20131416 (2003).","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"issue":"6","key":"35907_CR90","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.bbagen.2016.03.013","volume":"1860","author":"TN Gustafsson","year":"2016","unstructured":"Gustafsson, T. N. et al. Ebselen and analogs as inhibitors of Bacillus anthracis thioredoxin reductase and bactericidal antibacterials targeting Bacillus species, Staphylococcus aureus and Mycobacterium tuberculosis. Biochim. Biophys. Acta 1860(6), 1265\u20131271 (2016).","journal-title":"Biochim. Biophys. Acta"},{"key":"35907_CR91","unstructured":"Wan, J. et al. Benzoselenazole ketone compound and application thereof and bactericide (2021)."},{"key":"35907_CR92","unstructured":"Bender, C. O. et al. Use of small molecules for the treatment of Clostridium difficile toxicity (2015)."},{"issue":"1","key":"35907_CR93","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1021\/acschembio.8b00937","volume":"14","author":"M Garland","year":"2019","unstructured":"Garland, M. et al. Covalent modifiers of botulinum neurotoxin counteract toxin persistence. ACS Chem. Biol. 14(1), 76\u201387 (2019).","journal-title":"ACS Chem. Biol."},{"issue":"3","key":"35907_CR94","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.jmb.2006.11.073","volume":"366","author":"X Xue","year":"2007","unstructured":"Xue, X. et al. Production of authentic SARS-CoV M(pro) with enhanced activity: Application as a novel tag-cleavage endopeptidase for protein overproduction. J. Mol. Biol. 366(3), 965\u2013975 (2007).","journal-title":"J. Mol. Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35907-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35907-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35907-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T15:37:06Z","timestamp":1686065826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35907-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,6]]},"references-count":94,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["35907"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-35907-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1546114\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,6]]},"assertion":[{"value":"11 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9161"}}